Skip to main content
SpringerLink
Log in

Liposomal Influenza Vaccine

  • Adis New Drug Profile
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

▴ This trivalent liposomal influenza vaccine consists of purified influenza haemagglutinin inserted into a membrane of phosphatidylcholine and phosphatidylethanolamine. It contains 15μg of haemagglutinin per viral strain per dose.

▴ The vaccine is immunogenic in the elderly, in younger adults and in children and adolescents with or without cystic fibrosis.

▴ Seroconversion rates were significantly higher with the liposomal vaccine than with a subunit vaccine for 3 of 3 and 2 of 3 strains in 2 published studies. Seroconversion occurred in a significantly greater number of participants receiving the liposomal vaccine than in those receiving a whole virus vaccine for all 3 strains in 1 study.

▴ Seroprotection rates were significantly better with the liposomal vaccine than with a subunit vaccine for 2 of 3 and 1 of 3 strains in 2 trials, and greater than with a whole virus vaccine for 2 of 3 strains in 1 trial.

▴ In a study in children with cystic fibrosis, a single dose of the liposomal vaccine was reported to have greater immunogenicity than 2 half doses (statistical analysis not performed).

▴ Local adverse reactions such as pain at the injection site, local induration, redness and swelling are transient and usually mild.

▴ Liposomal influenza vaccine did not induce a mean antiphospholipid antibody response in elderly volunteers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Powers DC. Influenza virus vaccines. Drugs Today 1996 Apr-May; 32: 225–37

    Google Scholar 

  2. Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998 May 10; 47 RR-6: 1–26

    Google Scholar 

  3. Palache AM. Influenza vaccines: a reappraisal of their use. Drugs 1997 Dec; 54(6): 841–56

    Article  PubMed  CAS  Google Scholar 

  4. Glathe H, Lange W. Influenza vaccination in older patients: immunogenicity, epidemiology and available agents. Drugs Aging 1995 May; 6: 368–87

    Article  PubMed  CAS  Google Scholar 

  5. Glück R. Liposomal presentation of antigens for human vaccines. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995: 325–45

    Google Scholar 

  6. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products: note for guidance on harmonisation of requirements for influenza vaccines. London, England, 1997

  7. Glück R, Mischler R, Que JU, et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994 Jul 16; 344: 160–3

    Article  PubMed  Google Scholar 

  8. Conne P, Gauthey L, Vernet P. Immunogenicity of trivaient subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997 Oct; 15(15): 1675–9

    Article  PubMed  CAS  Google Scholar 

  9. Glück R et al. Virosomal influenza vaccine versus Inflexal Berna 1990/91. Swiss Serum and Vaccine Institute Berne. KV9009; 1990 (Data on file)

  10. De Bernardi di Valserra M. Comparison of two different formulations of the influenza vaccine for the season 1994/95 (Inflexal Berna® whole-virus and Inflexal Berne subunit IRIV. Swiss Serum and Vaccine Institute Berne. KV9414; 1995 (Data on file)

  11. Al-Hamdan Y, Ledermann H-J. Inflexal V Influenza Vaccine: clinical trial to assess the immunogenicity of the 1997/98-sea-son virosomal subunit influenza vaccine in elderly and young individuals according to EMEAregulations. Swiss Serum and Vaccine Institute Berne. KV9704; 1997 (Data on file)

  12. Halabi A, Al-Hamdan Y Clinical trial to assess the immunogenicity of the 1998/99-season virosomal subunit influenza vaccine in elderly and young individuals according to EMEA regulations. Swiss Serum and Vaccine Institute Berne. KV9805; 1998 (Data on file)

  13. Schaad UB,Buehlmann U, Burger R, et al. Comparison of immunogenicity and safety of a virosome and a subunit influenza vaccine in pediatric cystic fibrosis patients: a Swiss multicenter study [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1;Toronto

  14. Schaad UB, Buehlmann U, Burger R, et al. Comparison of immunogenicity and safety of a virosome and a subunit influenza vaccine in pediatric cystic fibrosis patients: a Swiss multicenter study [poster]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto

  15. Angius E. Comparison of two different formulations of influenza vaccine for the season 1994/95 in children (Inflexal Berna subunit IRIV and Agrippal Biocine subunit). Swiss Serum and Vaccine Institute Berne. KV9435; 1995 (Data on file)

  16. Gauthey L, Conne P, Vernet P, et al. Yearly revaccination of elderly persons with a virosomal influenza vaccine in comparison to a subunit virus influenza vaccine. Swiss Serum and Vaccine Institute Berne. KV9426; 1994 (Data on file)

  17. Saurwein-Teissl M, Zisterer K, Schmitt TL, et al. Whole virus influenza vaccine activates dendritic cells and stimulates cytokine production by peripheral blood mononuclear cells while subunit vaccines support T cell proliferation. Clin Exp Immunol 1998 Nov; 114: 271–6

    Article  PubMed  CAS  Google Scholar 

  18. Schaad UB, Bühlmann U, Burger R, et al. Randomized trial to compare the immunogenicity and safety of a virosomal and a subunit influenza vaccine in cystic fibrosis patients -Swiss multicenter study. Swiss Serum and Vaccine Institute Berne. KV9410; 1995 (Data on file)

  19. Conne P, Gauthey L, Vernet P, et al. Virosomal influenza vaccine versus Influvac 1993/94. Swiss Serum and Vaccine Institute Berne. KV9311; 1993 (Data on file)

  20. Glück R, Mischler R, Finkel B, et al. Inflexal Berna 1992/93 versus Virosomal Influenza Vaccine versus Virosomal Tetanus Influenza Vaccine versus Influvac Duphar 1992/93. Swiss Serum and Vaccine Institute Berne. KV9225; 1993 (Data on file)

  21. Cryz SJ, Que JU, Glück R. Avirosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 1996 Oct; 14(14): 1381–3 144

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag, 65901, Mairangi Bay, Auckland 10, New Zealand

    Kristin J. Holm & Karen L. Goa

Authors
  1. Kristin J. Holm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristin J. Holm.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holm, K.J., Goa, K.L. Liposomal Influenza Vaccine. BioDrugs 11, 137–144 (1999). https://doi.org/10.2165/00063030-199911020-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911020-00007

Keywords

Search

Navigation